Solid Biosciences (Solid Biosciences) Debt-to-Equity : 0.21 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Debt-to-Equity?

Solid Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.32 Mil. Solid Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $23.94 Mil. Solid Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $126.48 Mil. Solid Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Solid Biosciences's Debt-to-Equity or its related term are showing as below:

SLDB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.21
Current: 0.21

During the past 9 years, the highest Debt-to-Equity Ratio of Solid Biosciences was 0.21. The lowest was 0.01. And the median was 0.06.

SLDB's Debt-to-Equity is ranked worse than
57.38% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs SLDB: 0.21

Solid Biosciences Debt-to-Equity Historical Data

The historical data trend for Solid Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Debt-to-Equity Chart

Solid Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.04

0.01

0.14

0.21

Solid Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.14	0.15	0.17	0.19	0.21

Competitive Comparison of Solid Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Solid Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Debt-to-Equity falls into.

Solid Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Solid Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.324	+	23.941)	/	126.481
	=	0.21

Solid Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.324	+	23.941)	/	126.481
	=	0.21

Solid Biosciences (NAS:SLDB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Solid Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Solid Biosciences (Solid Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129

Website

https://www.solidbio.com

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan	officer: CFO & Treasurer	20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot	director, officer: Chief Executive Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton	officer: See Remarks	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe	officer: CSO, FA & Cardiac	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich	officer: Chief Technology Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan	officer: Chief Regulatory Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks	officer: Chief Medical Officer	C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris	officer: Chief Scientific Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn	director	141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116